Omalizumab Linked to Lower Heart Risk in Hives Patients
Patients with chronic hives saw lower cardiovascular disease rates on omalizumab compared to oral corticosteroids.
Updated on Oct. 26, 2026 in Allergies
Live Poll
Do you prioritize cardiovascular risk profiles when choosing medications for chronic inflammatory conditions?
A recent retrospective study shows that patients with chronic spontaneous urticaria treated with omalizumab had a lower risk of cardiovascular disease compared to those on oral corticosteroids. This finding may offer insights for patients and physicians weighing long-term treatment options for chronic hives.
Why it matters
Managing chronic hives often requires long-term medication, and this evidence helps clarify how different therapies may impact cardiovascular health over time. Understanding these risks is a vital part of the ongoing conversation between patients and their healthcare providers.
A retrospective cohort study analyzed outcomes for thousands of patients with chronic spontaneous urticaria to determine cardiovascular risk. Within three years, 3.55% of those treated with omalizumab developed cardiovascular disease, compared to 8.06% of those treated with oral corticosteroids.
The details
The study utilized clinical data from the US Collaborative Network of TriNetX to compare cardiovascular outcomes across different urticaria treatment paths. Researchers found a clear hierarchy of risk, where omalizumab was associated with the lowest incidence of cardiovascular disease, followed by second-generation antihistamines, with oral corticosteroids linked to the highest risk. The cohort had a mean age of approximately 43 years and consisted of about 77% women.
Timeline
October 21, 2026: Study results published online as a Letter.
Health Landscape
This research follows a growing trend of utilizing the US Collaborative Network of TriNetX to conduct large-scale observational studies on the long-term impacts of common treatments. It provides important data as clinicians continue to refine care strategies for chronic autoimmune and inflammatory conditions.
If you are currently managing chronic spontaneous urticaria, these findings are worth discussing with your doctor to understand how your specific medication profile fits into your overall heart health. Consider asking your physician about the long-term cardiovascular implications of your current treatment regimen.
The takeaway
Chronic hives treatments carry different long-term risk profiles that warrant careful consideration during routine checkups. Patients should track any changes in their cardiovascular health and maintain an open dialogue with their physician about the potential impacts of their prescribed therapies.
Further reading
Learn more about managing symptoms and treatment options on our Allergies page.
Source note: This article includes information reported by Medscape.
Live Poll
Do you prioritize cardiovascular risk profiles when choosing medications for chronic inflammatory conditions?
